<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Stock price movement on FinanClub</title>
    <link>https://finan.club/tags/stock-price-movement/</link>
    <description>Recent content in Stock price movement on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 16 Apr 2024 09:02:45 +0000</lastBuildDate><atom:link href="https://finan.club/tags/stock-price-movement/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 16 Apr 2024 09:02:45 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:176
Chances: The FDA approval of AstraZeneca&amp;rsquo;s Fasenra for patients with severe asthma aged six to 11 years presents a strong opportunity for growth in this market segment. Despite investor backlash over high executive pay, AstraZeneca&amp;rsquo;s continued approval of new drugs and expansion of its product line indicates potential for future success.</description>
    </item>
    
  </channel>
</rss>
